09 May 2007 - Affitech AS announced that they have signed a research and licensing agreement with Roche to produce fully human monoclonal antibodies against an unnamed oncology target. The agreement tasks Affitech with first using their proprietary phagemid library, high throughput screening technology and antibody engineering platforms to identify candidate antibodies which Roche would then utilize for further development and commercialization. The financial terms of the collaboration include research fees, milestone payments and royalties on net sales upon commercialization of any product.
 |
www.bionity.com/news/e/64492 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/64492 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |